Tyrosine kinase inhibitors induce alternative spliced BCR‐ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR‐ABL
Open Access
- 21 April 2020
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 111 (7), 2361-2373
- https://doi.org/10.1111/cas.14424
Abstract
To elucidate dynamic changes in native BCR‐ABL and alternatively spliced tyrosine kinase inhibitor (TKI)‐resistant but function‐dead BCR‐ABLIns35bp variant, following commencement or discontinuation of TKI therapy, each transcript was serially quantified in patients with chronic myeloid leukemia (CML) by deep sequencing. Since both transcripts are measured together by conventional polymerase chain reaction as a common International Scale (IS), deep sequencing method was used for quantifying such BCR‐ABL variants. At the initial diagnosis, seven of nine patients presented a small fraction possessing BCR‐ABLIns35bp, accounting for 0.8% of the total IS BCR‐ABL, corresponding to an actual BCR‐ABLIns35bp value of 1.1539% IS. TKI rapidly decreased native BCR‐ABL but not BCR‐ABLIns35bp, leading to an initial increase in the proportion of BCR‐ABLIns35bp. Thereafter, both native BCR‐ABL and BCR‐ABLIns35bp gradually decreased on the course of TKI treatment, whereas small populations positive for TKI‐resistant BCR‐ABLIns35bp continued fluctuating at low levels, possibly underestimating the molecular response (MR). Following TKI discontinuation, sequencing analysis of 54 patients revealed a rapid relapse, apparently derived from native BCR‐ABL+ clones. However, IS fluctuating at low levels around MR4.0 marked a predominant persistence of cells expressing function‐dead BCR‐ABLIns35bp, suggesting that TKI resumption was unnecessary. We clarified the possible mechanism underlying mis‐splicing BCR‐ABLIns35bp, occurring at the particular pseudo‐splice site within intron8, which can be augmented by TKI treatment through inhibition of RNA polymerase II phosphorylation. No mutations were found in spliceosomal genes. Therefore, monitoring IS functional BCR‐ABL extracting BCR‐ABLIns35bp would lead us toward a correct evaluation of MR status thus determining an adequate therapeutic intervention.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 35 references indexed in Scilit:
- CTD serine-2 plays a critical role in splicing and termination factor recruitment to RNA polymerase II in vivoNucleic Acids Research, 2012
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2011
- The Spliceosome as an Indicted Conspirator in Myeloid MalignanciesCancer Cell, 2011
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsThe New England Journal of Medicine, 2011
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityJCI Insight, 2011
- Human Splicing Finder: an online bioinformatics tool to predict splicing signalsNucleic Acids Research, 2009
- BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase InhibitorsActa Haematologica, 2009
- The Protein Arginine Methyltransferase Prmt5 Is Required for Myogenesis because It Facilitates ATP-Dependent Chromatin RemodelingMolecular and Cellular Biology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCRProceedings of the National Academy of Sciences of the United States of America, 2006